Drug intelligence / Profile preview

T1D-101

Development stage: Preclinical
Lead developer: 4immune Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

T1D-101 is an investigational cell therapy being developed by 4immune Therapeutics for the treatment of early-onset Type 1 Diabetes. The therapy utilizes a Chimeric Autoantibody Receptor (CAL) or Chimeric Antigen Receptor (CAR) T-cell platform designed to selectively target and eliminate the autoreactive T cells that attack and destroy insulin-producing pancreatic beta cells. By depleting these pathogenic T-cell populations, T1D-101 aims to preserve residual beta-cell mass and maintain endogenous insulin production. The program is currently in the IND-enabling stage of development.

Beyond the preview

Go deeper on T1D-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on T1D-101.

Explore the full profile